ValueQ4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses61.22 M64.13 M72.94 M69.54 M267.82 MResearch & development34 K41 K78 K62 K215 K영업 이익-1.44 B2.09 M-22.28 M-26.39 M-1.49 BNon-Operating Income, Total54.91 M3.83 M-12.31 M8.09 M54.53 MInterest expense, net of interest capitalized—————Non-Operating Income, excl. Interest Expenses71.59 M3.83 M-12.31 M8.09 M71.21 MUnusual income/expense-16.68 M————Pretax income-1.39 B-772 K-39.96 M-23.26 M-1.46 BEquity in earnings—————Taxes-125.14 M-2.29 M3.55 M1.97 M-121.91 MNon-controlling/minority interest4.9 M1.83 M1.42 M1.34 M9.5 MAfter tax other income/expense3.71 M-282 K-1.49 M-635 K1.3 MNet income before discontinued operations-1.27 B-322 K-44.93 M-26.57 M-1.34 BDiscontinued operations—————Net income-1.27 B-322 K-44.93 M-26.57 M-1.34 BDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders-1.27 B-322 K-44.93 M-26.57 M-1.34 BBasic earnings per share (Basic EPS)-14.520-0.41-0.24-15.17Diluted earnings per share (Diluted EPS)-14.520-0.41-0.24-15.17Average basic shares outstanding89.03 M106.03 M110.34 M112.68 M418.08 MDiluted shares outstanding89.03 M106.03 M110.34 M112.68 M418.08 MEBITDA-1.41 B17.65 M-6.32 M-9.64 M-1.41 BEBIT-1.44 B2.09 M-22.28 M-26.39 M-1.49 BCost of revenue156.9 M152.03 M160.01 M151.78 M620.72 MOther cost of goods sold—————Depreciation & amortization (cash flow)34.08 M15.56 M15.96 M16.74 M82.34 M
Tilray Brands Inc - Class 2
Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand, Latin America, with growing facilities in Germany, Portugal and the United Kingdom.
In December 2020, the company announced a merger with Aphria, and now operates under the Tilray name and its ticker symbol on NASDAQ and the Toronto Stock Exchange.
Tilray also owns several breweries and was ranked by the Brewers Association as the 4th largest craft beer company in the US in 2025.